Key takeaways:

Neoadjuvant chemotherapy significantly lowered 90-day postoperative mortality for advanced ovarian cancer across all volume tertiles.

Long-term survival improved at high-volume hospitals with high utilization.

Institutions that had higher utilization of neoadjuvant chemotherapy for advanced-stage ovarian cancer had significantly lower rates of 90-day postoperative mortality compared with those that use it the least.

Researchers found the association applied at high-, average- and low-volume hospitals, and women treated at high-volume hospitals with high utilization also had their 5-year life expectancy extended 4 months.

Data derived from Abel MK, et al. JAMA Netw Open. 2025;doi:10.1001/jamanetworkopen.2025.23434.

Alexander Melamed

“There’s no evidence that there is a

See Full Page